SCHEMBL6336364

SCHEMBL6336364

CC1CCCCN1.NC(=O)Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.39
FDPS P14324 1/20 0.35
NOS2 P35228 2/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
SLC6A3 Q01959 4/20 0.33
SLC6A2 P23975 3/20 0.33
SLC6A4 P31645 3/20 0.33
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
KMT2A Q03164 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
ATM Q13315 1/20 0.32
CYP2D6 P10635 1/20 0.32
GLI1 P08151 1/20 0.32
MEN1 O00255 1/20 0.32
BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11682842 0.86 FDPS (0.36) EPHX1FDPSNOS2SLC6A3SLC6A2
SCHEMBL11684883 0.82 FDPS (0.36) EPHX1FDPSNOS2NOS3NOS1
Iodoacetamide SCHEMBL11685191 0.82 LMNA (0.42) EPHX1FDPSNOS2NOS3NOS1
SCHEMBL231477 0.81
SCHEMBL24886 0.81
SCHEMBL251844 0.81
Acetic Acid SCHEMBL30834058 0.80 SLC6A3 (0.41) FDPSSLC6A3SLC6A2SLC6A4CYP2C9
SCHEMBL10578750 0.79
SCHEMBL15929564 0.78 TSHR (0.45) FDPSSLC6A3SLC6A2SLC6A4CYP2C9
Iodide SCHEMBL20815441 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911477-B2 Muscarinic receptor agonists PFIZER INC. (US) 2005-06-28 US disclosed
US-20030171349-A1 Novel muscarinic receptor agonists VILLALOBOS ANABELLA (US) 2003-09-11 US disclosed
US-20020103194-A1 Novel muscarinic receptor agonists VILLALOBOS ANABELLA (US) 2002-08-01 US disclosed
EP-0805153-B1 Novel muscarinic receptor agonists PFIZER (US) 2001-11-14 EP disclosed
US-6093733-A FOR THE TREATMENT OR PREVENTION OF DISEASES THE TREATMENT OR PREVENTION OF WHICH IS MEDIATED BY MUSCARINIC RECEPTOR AGONISM; ALZHEIMER'S DISEASE PFIZER INC. 2000-07-25 US disclosed
EP-0805153-A1 Novel muscarinic receptor agonists PFIZER INC. (US) 1997-11-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171349-A1 Novel muscarinic receptor agonists CHRM3, CHRM4, CHRM2 EPHX1 767/4885FDPS 3706/4885NOS2 2019/4885
US-20020103194-A1 Novel muscarinic receptor agonists CHRM3, CHRM4, CHRM2 EPHX1 786/4885FDPS 3851/4885NOS2 2026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.